当前位置: X-MOL 学术J. Am. Acad. Dermatol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Psoriasis: Which therapy for which patient
Journal of the American Academy of Dermatology ( IF 13.8 ) Pub Date : 2018-07-11 , DOI: 10.1016/j.jaad.2018.06.056
Shivani B. Kaushik , Mark G. Lebwohl

Despite the availability of several new systemic agents for psoriasis treatment, choosing the right therapy in certain patient populations can be challenging. There are few up-to-date reviews on systemic drugs for moderate to severe psoriasis in pregnant and pediatric patients and in patients with concomitant chronic infections, such as hepatitis, HIV, and latent tuberculosis. These groups are usually excluded from clinical trials, and much of the available evidence is based on anecdotal case reports and case series. As a chronic disease, psoriasis requires long-term treatment, and there are concerns of adverse maternal–fetal outcomes, long-term side effects in children, and the reactivation of latent infections with the use of systemic agents in these patients. The second article in this continuing medical education series provides insights for choosing appropriate systemic agents for treating moderate to severe psoriasis in pregnant and pediatric patients and in the setting of chronic infections, such as hepatitis, HIV, and latent tuberculosis.



中文翻译:

牛皮癣:适合哪个患者的疗法

尽管有几种用于牛皮癣治疗的新的全身性药物,但是在某些患者人群中选择正确的治疗方法仍然是一项挑战。对于孕妇和儿科患者以及伴发慢性感染(例如肝炎,HIV和潜伏性结核病)的中度至重度牛皮癣的全身性药物,最新的评论很少。这些人群通常被排除在临床试验之外,许多可用的证据都是基于轶事病例报告和病例系列。作为一种慢性疾病,牛皮癣需要长期治疗,并且担心这些患者的母婴结局不良,儿童长期副作用以及使用全身性药物重新激活潜伏感染。

更新日期:2018-07-11
down
wechat
bug